Latest news with #ETS2
Yahoo
20-05-2025
- Health
- Yahoo
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD -- MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ('Pasithea' or the 'Company'), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease (IBD). This study was conducted at the Francis Crick Institute in London, U.K. by Dr. James Lee, a gastroenterologist and Clinician Scientist Group Leader at the Genetic Mechanisms of Disease Laboratory. Dr. Lee was the lead author of a landmark 2024 Nature paper that identified ETS2 as a master regulator of inflammatory responses in IBD, and uncovered a novel genetic mechanism behind the disease, which pointed to a new, potentially effective treatment strategy through MEK inhibition. In this new study RNA sequencing was used to measure gene expression, with PAS-004 consistently outperforming the FDA-approved MEK inhibitor selumetinib across all tested doses (0.01 μM, 0.1 μM, and 1 μM), showing greater downregulation of ETS2 target genes, as well as experimentally validated MEK1/2 pathway genes. These data suggest more robust and durable MEK inhibition by PAS-004 under inflammatory conditions. Key findings of this study are: - : At all doses, PAS-004 showed greater downregulation of ETS2-regulated genes than selumetinib. - : PAS-004 significantly reduced ETS2-dependent functions such as cytokine production, phagocytosis, and reactive oxygen species (ROS) generation, all known to be central to chronic inflammation. - : Gene Set Enrichment Analysis revealed that PAS-004's effects more closely mirrored ETS2 knockout profiles, with a higher normalized enrichment score (-3.96 vs -3.56) and greater statistical significance (1.2 x 10⁻²⁵⁰ vs 3.7 x 10⁻⁷⁴) as compared to selumetinib. Dr. Lee commented, 'Collectively, these in vitro data suggest that, compared to selumetinib, PAS-004 is likely to provide superior inhibition of the macrophage inflammatory pathways orchestrated by ETS2. Blocking single cytokines is a common strategy used to treat chronic inflammatory diseases, but growing evidence suggests that targeting several at once may be a better approach. Blocking ETS2 signaling through MEK1/2 inhibition affects multiple cytokines, including TNFα and IL-23, which are individually targeted by existing therapies, and IL-1β, which has been implicated in treatment resistance and is not directly modulated by JAK inhibitors.' 'JAK inhibitors have dominated the IBD oral treatment landscape over the last few years and we now have genetic evidence that MEK inhibition should affect a broader range of pathogenic cytokines including IL-1β, a critical cytokine that JAK inhibitors do not impact,' commented Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. Dr. Marques continued 'Based on the low level of adverse events and tolerable safety data we have observed in our Phase 1 clinical trial in advanced cancer patients, we believe PAS-004 has the potential to be a new oral treatment option for those suffering from inflammatory diseases such as IBD and we look forward to continuing to demonstrate proof-of-concept for PAS-004 in these additional indications.' Dr. Larry Steinman, Executive Chairman of Pasithea, added, 'I have studied inflammation and inflammatory pathways for over 50 years and today's results are exciting as we consider better drugs targeting inflammatory conditions. These preclinical results suggest PAS-004's ability to block ETS2 signaling and target multiple cytokines opens the potential for testing PAS-004 in large market inflammatory indications.' About Pasithea Therapeutics Corp. Pasithea is a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, RASopathies and MAPK pathway driven tumors. Forward Looking Statements This press release contains statements that constitute 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company's ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company's Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company's current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company's plans, assumptions, expectations, beliefs and objectives, the success of the Company's current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Pasithea Therapeutics Contact Patrick GaynesCorporate Communicationspgaynes@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
09-05-2025
- Business
- Business Wire
ICE Launches EU Carbon Allowance 2 Futures
AMSTERDAM & LONDON & NEW YORK--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE:ICE), a leading global provider of technology and data, announced the launch this week of EU Carbon Allowance (EUA) 2 futures, with the contract now available to trade alongside ICE's benchmark EUA futures and options, the most liquid carbon derivatives market in the world. The EUA 2 futures contract launched on May 6, 2025, with the first trades taking place on the same day, totaling the equivalent of 5,000 EUA 2 allowances. Reflecting how many carbon markets are expanding their scope and coverage, the European Union has created a new emissions trading system called the Emissions Trading System 2 (ETS2) which is designed to cover carbon dioxide emissions from fuel combustion in buildings and road transport. The ETS2 is expected to become operational in 2027 and double the scope of the existing EU ETS to 80% of the EU economy, expanding the number of covered entities to approximately 20,000. '2025 marks twenty-five years since ICE began investing in and building global energy and environmental markets, and today ICE's markets provide the price signals and liquidity that allow companies to manage the uncertainties of decarbonization,' said Gordon Bennett, Global Head of Environmental Markets at ICE. 'The carbon price set by the EU ETS2 can provide a market incentive for investments in building renovations and low-emissions mobility and by offering futures covering this new system, ICE is delivering price signals to customers who are mandated to account for the cost of pollution in these new sectors.' 'Macquarie is pleased to participate in the launch of the ICE EUA 2 futures contract,' said German Tyeles, a Senior Vice President within Macquarie's Commodities and Global Markets business. 'We have supported clients across environmental markets worldwide for almost two decades and look forward to putting our commodities expertise to work in this emerging space.' 'We are excited to see ICE yet again playing a pioneering role in providing market participants such as Mercuria with the necessary instruments to enable price discovery in these new sectors covered in the EU's approach to carbon pricing,' said James Cooper, Head of Origination EMEA, Environmental Products at Mercuria. 'ICE's launch of an EUA 2 contract marks a significant milestone in the evolution of Europe's carbon markets, enhancing price transparency and strengthening Trafigura's ability to manage risk on behalf of their customers in newly affected sectors,' said Hannah Hauman, Global Head of Carbon Trading at Trafigura. 'Statkraft strongly believes in carbon markets as a market-based tool to fight climate change and renew the way the world is powered,' said Misja Nuyens, Head of Global Environmental Markets at Statkraft. 'We have been supportive of the EU ETS as a core in the EU energy transition from the very start in 2005 and contributed to the liquidity of the market through our trading activities. Statkraft is therefore pleased to witness the launch of the EUA 2 contract on ICE.' 'We fully support transparent, market-based platforms that enable fair carbon dioxide pricing,' said Dr. Arne Weber, Head of Power, Gas & Emissions at Mabanaft. 'These new instruments offer a valuable opportunity to manage long-term carbon dioxide risks and provide the essential price signals needed to drive investment and decision-making in the energy transition. A well-functioning market is fundamental to achieving carbon dioxide management in an economically viable way.' 'The launch of the EUA 2 futures contract is a critical step in helping market participants prepare for the expansion of the EU carbon market. We at Vertis see a growing interest from companies, particularly in sectors not currently covered by ETS1, as they assess the financial implications of future compliance,' said Bartosz Wilamowski, Head of Sales - EU ETS at Vertis. 'Unlike the early days of ETS1, we expect ETS2 to drive more immediate and material cost exposure. This new contract brings much-needed price transparency, enabling businesses to better plan and manage their carbon-related financial risks.' 'Global Factor welcomes the launch of ICE's EUA 2 futures contract. This new instrument will play a crucial role in sending clear price signals to support the decarbonization of road transport and residential energy use at the lowest cost,' said Kepa Solaun, CEO of Global Factor. 'It also offers an essential tool for managing the risks faced by the companies we work with.' The EUA 2 futures contract is the latest addition to ICE's global environmental markets which offer the most liquid venues to trade European, North American, and U.K. environmental programs. The equivalent to over $1 trillion worth of environmental contracts trade on ICE each year and since launch over 173 billion carbon allowances, 655 million renewable energy certificates and over 6 billion tons of carbon credits have traded across ICE's global markets. About Intercontinental Exchange Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE's futures, equity, and options exchanges – including the New York Stock Exchange – and clearing houses help people invest, raise capital and manage risk. We offer some of the world's largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology , we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines and automates industries to connect our customers to opportunity. Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here . Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading 'Key Information Documents (KIDS).' Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 – Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 6, 2025.
Gulf Insider
08-03-2025
- Business
- Gulf Insider
New EU Carbon Market Set To Hammer Households And Small Businesses
The European Union's (EU) new emissions trading system, expected to take effect in 2027, is set to hike prices for home heating and transportation, research firm BloombergNEF says in a new report. The new EU Emissions Trading System for buildings, road transport, and small industry, dubbed ETS2, is scheduled to become fully operational in 2027. ETS2 will cover and address the carbon dioxide (CO2) emissions from fuel combustion in buildings, road transport, and additional sectors, mainly small industry not covered by the existing Emissions Trading System – EU ETS. 'So far, emission reductions in those sectors have been insufficient to put the EU on a firm path towards its 2050 climate neutrality goal. The carbon price set by the ETS2 will provide a market incentive for investments in building renovations and low-emissions mobility,' the European Commission says. Although it will be a 'cap and trade' system like the existing EU ETS, the ETS2 will cover emissions upstream. This means that it will be fuel suppliers, rather than end consumers such as households or car users, that will be required to monitor and report their emissions. User may not pay directly, but fuel suppliers are likely to pass on the higher costs due to the carbon emissions trading. Two years after the 2027 launch, the price of CO2 could jump to as much as $161 (149 euros) per metric ton in 2029, according to BloombergNEF's analysis. This would be more than double the current price of CO2 under the existing EU ETS trading system for emissions from industry and power plants. Click here to read more.. .
